2 results
Approved WMOCompleted
To determine the safety and effectiveness of the PROMUS Element* Everolimus-Eluting Coronary Stent System (Boston Scientific Corporation [BSC], Natick, MA) for the treatment of patients with up to 2 de novo atherosclerotic lesions
Approved WMOCompleted
The primary objective of this clinical investigation is to demonstrate that the qualification rate with anatomic lead placement is non-inferior to the qualification rate with targeted lead placement (tonic paresthesia guided) for the BurstDRTM trial…